全文获取类型
收费全文 | 228篇 |
免费 | 22篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 29篇 |
妇产科学 | 5篇 |
基础医学 | 39篇 |
口腔科学 | 8篇 |
临床医学 | 21篇 |
内科学 | 63篇 |
皮肤病学 | 4篇 |
神经病学 | 9篇 |
特种医学 | 2篇 |
外科学 | 21篇 |
综合类 | 4篇 |
预防医学 | 16篇 |
眼科学 | 6篇 |
药学 | 20篇 |
中国医学 | 1篇 |
肿瘤学 | 6篇 |
出版年
2024年 | 2篇 |
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 3篇 |
2019年 | 6篇 |
2018年 | 14篇 |
2017年 | 13篇 |
2016年 | 11篇 |
2015年 | 18篇 |
2014年 | 25篇 |
2013年 | 21篇 |
2012年 | 24篇 |
2011年 | 22篇 |
2010年 | 13篇 |
2009年 | 13篇 |
2008年 | 15篇 |
2007年 | 10篇 |
2006年 | 8篇 |
2005年 | 4篇 |
2004年 | 4篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 3篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1987年 | 1篇 |
排序方式: 共有254条查询结果,搜索用时 15 毫秒
1.
Gholamhossein Ajami Ahmad Ali Amirghofran Hamid Amoozgar Mohammad Borzouee 《Iranian journal of pediatrics.》2015,25(5)
Introduction:
Truncus arteriosus with intact ventricular septum is a rare and unique variant of persistent truncus arteriosus (PTA) which usually presents with central cyanosis and congestive heart failure in neonate and early infancy. Associated cardiac and non-cardiac anomalies may affect morbidity and mortality of these patients.Case Presentation:
We describe clinical presentation, echocardiography and angiographic features of a 7-month old boy with PTA and intact ventricular septum who underwent surgical repair of the anomaly at our institution. Operative findings, surgical procedure and short-term outcome are reported.Conclusions:
While our patient had systemic pulmonary arterial pressure at the time of complete surgical repair, it was improved after surgery. 相似文献2.
3.
4.
Hosein Shabaninejad Gholamhossein Mehralian Arash Rashidian Ahmad Baratimarnani Hamid Reza Rasekh 《Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences》2014,22(1):35
Background
Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies’ competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS).Results
The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area.Conclusion
This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets’ needs. 相似文献5.
Mariko L. Bennett F. Chris Bennett Shane A. Liddelow Bahareh Ajami Jennifer L. Zamanian Nathaniel B. Fernhoff Sara B. Mulinyawe Christopher J. Bohlen Aykezar Adil Andrew Tucker Irving L. Weissman Edward F. Chang Gordon Li Gerald A. Grant Melanie G. Hayden Gephart Ben A. Barres 《Proceedings of the National Academy of Sciences of the United States of America》2016,113(12):E1738-E1746
6.
Candice Alexandra Grzelak Luciano Gastón Martelotto Nicholas David Sigglekow Bramilla Patkunanathan Katerina Ajami Sarah Ruth Calabro Benjamin James Dwyer Janina Elke Eleonore Tirnitz-Parker D. Neil Watkins Fiona Jane Warner Nicholas Adam Shackel Geoffrey William McCaughan 《Journal of hepatology》2014
7.
8.
9.
Hamid Amoozgar Somaieh Mehdizadeh Gholamhossein Ajami Soheila Alyasin Mohammad Borzoee Saeed Abtahi Siros Cheriki 《Pediatric cardiology》2009,30(7):936-940
Myocarditis is a well-recognized component of Kawasaki disease, with left ventricular dysfunction occurring in more than half
of patients during the acute phase. The purpose of this study was to evaluate myocardial function in patients with Kawasaki
disease using pulsed tissue Doppler imaging (TDI). Twenty-five patients with the diagnosis of acute Kawasaki disease were
enrolled in the study. All patients underwent echocardiographic studies at the time of diagnosis of the disease, in its acute
phase, prior to treatment, and then 4 weeks later. For an aged-matched control group with fever and no cardiac disease, the
same echocardiographic evaluations were performed. Peak velocities of systolic (Sa), early diastolic (Ea), and late diastolic
(Aa) motion of the annulus were obtained at the lateral and septal sides in apical four-chamber view, and TDI-derived myocardial
performance index (TDI-MPI) was also calculated. Peak Ea velocity of lateral mitral annulus was decreased significantly during
the acute phase of illness (14 ± 4.40 vs. 17.67 ± 4.41; P = 0.028). In seven patients with carditis, changes in Ea-to-Aa ratio of septum (1.28 ± 0.278 vs. 1.78 ± 0.49; P = 0.018) and lateral mitral annulus (1.23 ± 0.496 vs. 2.11 ± 0.822; P = 0.014) were statistically significant but TDI-MPI showed no statistically significant changes. This study showed that peak
mitral annular Ea velocities obtained by TDI were significantly altered in the acute phase of Kawasaki disease. TDI- MPI does
not add an incremental benefit to other indexes of myocardial performance for comprehensive myocardial function in the acute
phase of Kawasaki disease. 相似文献
10.
Hossein Khorramdelazad Elham Hakimizadeh Gholamhossein Hassanshahi Mohammadtaghi Rezayati Hossein Sendi Mohammad Kazemi Arababadi 《Journal of medical virology》2013,85(6):964-968
CCR5 is an important chemokine receptor involved in the recruitment of specific anti‐viral immune cells (e.g., NK cells and T cytotoxic cells) to the liver. Previous studies indicated that the Δ 32 mutation in CCR5 gene led to inactivation of CCR5. Several conflicting studies have suggested that this mutation may be associated with either recovery or persistence of HBV infection. The main purpose of this study was to compare the frequency of the Δ 32 mutation within the CCR5 gene in a group of patients infected chronically with HBV with healthy individuals from South‐East of Iran. Sixty patients with chronic HBV infection as well as 300 age‐, and sex‐match healthy individuals were enrolled in this study. Gap‐PCR was applied to determine the frequency of CCR5 Δ 32 mutation in both groups. The results demonstrated that none of the patients infected with HBV carried the CCR5 Δ 32 mutation while, 3 (1%) of the healthy individuals were found to be heterozygotic for this mutation. The CCR5 Δ 32 mutation is not a prevalent mutation in either the patients infected chronically with HBV or their health counterparts in the South‐East region of Iran. This may be attributed to either different genetic settings of the investigated population or lack of any significant correlation between this mutation and HBV pathogenicity. J. Med. Virol. 85: 964–968, 2013. © 2013 Wiley Periodicals, Inc. 相似文献